Proteomics & Protein Research | GenomeWeb

Proteomics & Protein Research

Under new ownership after being acquired by GHO Capital, the company will consider expanding its business through acquisitions and moving into new geographies.

The company plans to launch the 12-protein panel as a CLIA test for longitudinal monitoring of cardiovascular disease, kidney disease, and diabetes.

At the National Center for Quantitative Biology of Complex Systems, scientists hope mass spec will drive new biological questions and vice versa.

The firm is developing protein therapies incorporating synthetic amino acids coded for by "unnatural" base pairs developed at The Scripps Research Institute.

GHO, a London-based investment firm, purchased the company for an undisclosed amount from Chicago Growth Partners, Caprion's majority shareholder since 2012.